1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:31 2022-06-30 am EDT
318.55 CHF   -0.34%
06/29GLOBAL MARKETS LIVE : Novartis, Tesla, Disney, Sony, Walmart...
06/29ROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
06/29Switzerland's Roche Introduces New Tissue Staining Platform For Cancer Diagnostics
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces First Quarter Sales 2022

04/25/2022 | 09:24am EDT

F. Hoffmann-La Roche Ltd. (hereafter 'Roche') [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced its first quarter sales 2022 (January 1 - March 31, 2022).

Roche owns 59.89% of Chugai's outstanding shares (61.16% of voting rights) as of the end of December 2021.

Its investor update and presentation materials can be found on its website (https://www.roche.com/).

Chugai's performance for the period of January 1 to March 31, 2022 is included in the announced Roche Group's results.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.,

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.78% 3444 Delayed Quote.-5.54%
ROCHE HOLDING AG -0.34% 318.55 Delayed Quote.-15.68%
All news about ROCHE HOLDING AG
06/29GLOBAL MARKETS LIVE : Novartis, Tesla, Disney, Sony, Walmart...
06/29ROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
06/29Switzerland's Roche Introduces New Tissue Staining Platform For Cancer Diagnostics
MT
06/29Roche Launches New Benchmark Ultra Plus System for Cancer Diagnostics Enabling Timely, ..
CI
06/28Novartis to cut up to 8,000 jobs globally
RE
06/28Roche Launches VENTANA DP 600 slide scanner for Digital Pathology, Enhancing Patient Ca..
CI
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/23Novartis wins U.S. approval for targeted cancer drug combination
RE
06/21KENYA : Ministry signs agreement to enhance access to breast cancer treatment
AQ
06/21KENYA : Ministry signs agreement to enhance access to breast cancer treatment Breast cance..
AQ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 723 M 66 734 M 66 734 M
Net income 2022 14 947 M 15 653 M 15 653 M
Net Debt 2022 11 260 M 11 792 M 11 792 M
P/E ratio 2022 17,0x
Yield 2022 3,04%
Capitalization 260 B 273 B 273 B
EV / Sales 2022 4,26x
EV / Sales 2023 4,10x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 318,55 CHF
Average target price 386,26 CHF
Spread / Average Target 21,3%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.68%273 835
JOHNSON & JOHNSON3.46%465 732
ELI LILLY AND COMPANY17.38%290 752
PFIZER, INC.-11.21%285 819
ABBVIE INC.13.12%272 382
NOVO NORDISK A/S7.29%251 811